

April 2, 2020



ResMed Statement on DPA

SAN DIEGO--(BUSINESS WIRE)-- ResMed (NYSE: RMD, ASX: RMD) has released the following statement regarding today's [*White House Memorandum on Order Under the Defense Production Act Regarding the Purchase of Ventilators*](#):

"ResMed is pleased to see the White House prioritize access to critical ventilator components, enabling not only ResMed but all industry-leading ventilator manufacturers to speed up both production and delivery of lifesaving devices to patients who need them most.

"We encourage automakers, aerospace equipment producers, and other non-ventilation manufacturers to help us source or create more of these components and accessories for ventilators, strengthening the supply chain that all ventilator makers are drawing from to help meet this rising global demand and save lives."

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit [ResMed.com](https://www.resmed.com) and follow @ResMed.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200402005886/en/>

For media

Jayne Rubenstein
+1 858.836.6798
news@resmed.com

For investors

Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Source: ResMed